Skip to main content
SpringerLink
Log in

Bevacizumab less costly, just as safe as ranibizumab in AMD

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kmietowicz Z. Cheaper alternative for macular degeneration is as safe as licensed drug, review finds. BMJ 349: 16 Sep 2014. Available from: URL: http://dx.doi.org/10.1136/bmj.g5618

    Google Scholar 

  2. Moja L et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration (Review). Internet Document : 16 Sep 2014. Available from: URL: http://doi.wiley.com/10.1002/14651858.CD011230.pub2

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bevacizumab less costly, just as safe as ranibizumab in AMD. Reactions Weekly 1519, 12 (2014). https://doi.org/10.1007/s40278-014-3431-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-014-3431-8

Search

Navigation